Related Experiment Videos
Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study
G J Lammers1, J Arends, A C Declerck
1Department of Neurology, Leiden University Hospital, The Netherlands.
Sleep
|April 1, 1993
Summary
Gammahydroxybutyrate (GHB) effectively treats narcolepsy symptoms, significantly reducing hallucinations and daytime sleep attacks. This study shows GHB is a well-tolerated option for managing narcolepsy.
Area of Science:
- Neurology
- Sleep Medicine
- Pharmacology
Background:
- Narcolepsy is a chronic neurological disorder affecting sleep-wake cycles.
- Current treatments for narcolepsy often have limitations or side effects.
Purpose of the Study:
- To evaluate the efficacy and tolerability of gammahydroxybutyrate (GHB) in treating narcolepsy.
- To assess GHB's impact on clinical symptoms and polysomnographic measures.
Main Methods:
- A randomized, double-blind, placebo-controlled, cross-over trial involving 24 narcolepsy patients.
- Treatment duration was 4 weeks with GHB at 60 mg/kg/night.
- Assessment included clinical evaluations and polysomnography.
Main Results:
- GHB significantly reduced hypnagogic hallucinations, daytime sleep attacks, and subjective sleepiness compared to placebo.
- GHB stabilized nocturnal rapid eye movement (REM) sleep by decreasing wakefulness and awakenings.
- A trend towards increased slow-wave sleep was observed, though cataplexy reduction was not statistically significant.
Conclusions:
- Gammahydroxybutyrate (GHB) is an effective treatment for key narcolepsy symptoms.
- GHB demonstrates good tolerability with few mild adverse events.
- GHB offers a promising therapeutic option for narcolepsy management.